ORCHARD PARK, NY, July 28 /PRNewswire-FirstCall/ -- European Laboratory Approval MINRAD announced today that it has successfully passed an audit of its Wasquehal, France subsidiary. It now has AFSSAPS (French pharmaceutical regulatory agency) approval to open as a French Pharmaceutical Establishment. Among other functions, the laboratory in Wasquehal will complete batch release testing for its pharmaceutical partners within the European community. The laboratory was developed in cooperation with the company's Northern European partner, Mylan. (NYSE:MYL) CE Mark Renewal The company also announces its image guidance manufacturing facility located in Orchard Park, NY has successfully completed a BSI quality systems audit and has received renewal of its CE certification. This ISO 13485: 2003 certification is required to distribute and sell its medical devices within the EU member countries. MINRAD now has 38 image guidance distribution agreements covering 40 countries. Sevoflurane Shelf Life Extension MINRAD also announces completion of 3-year stability testing of its Sojourn(TM) Sevoflurane anesthetic agent. Sojourn(TM), manufactured at its pharmaceutical plant in Bethlehem, PA, can now be labeled with 3-year expiration dating, as approved by the United States Food & Drug Administration. Currently, the company has marketing authorization for Sevoflurane in 17 countries, is selling in 15 countries, and is pursuing three year expiration dating in these regions. CONTACT: Dennis Goupil Chief Technical Officer E-mail: Tel: 610-974-9760 About the Company MINRAD International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com. The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, MINRAD International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of MINRAD International's Form 10-KSB-A, filed with the Securities and Exchange Commission on April 21, 2008. Although MINRAD International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. DATASOURCE: MINRAD International, Inc. CONTACT: Dennis Goupil, Chief Technical Officer of MINRAD International, Inc., +1-610-974-9760, Web site: http://www.minrad.com/

Copyright